---
layout: post
title: "Prospective Grant of an Exclusive Patent License: NCGC00413972 and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies"
date: 2026-02-05 18:58:23 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-04829
original_published: 2022-03-08 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: NCGC00413972 and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 08, 2022 00:00 UTC
**Document Number:** 2022-04829

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to Macala Bio, Inc. located in 1000 NW Wall Street, Suite 220, Bend, OR 97703.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/08/2022-04829/prospective-grant-of-an-exclusive-patent-license-ncgc00413972-and-its-related-analogs-consisting-of)
- API: https://www.federalregister.gov/api/v1/documents/2022-04829

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
